Representative Jefferson Shreve (R-Indiana) recently sold shares of Repligen Co. NASDAQ: RGEN. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $15,001 and $50,000 in Repligen stock on April 7th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.
Representative Jefferson Shreve also recently made the following trade(s):
- Purchased $50,001 - $100,000 in shares of Chipotle Mexican Grill NYSE: CMG on 4/17/2025.
- Purchased $50,001 - $100,000 in shares of Applied Materials NASDAQ: AMAT on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of Caterpillar NYSE: CAT on 4/17/2025.
- Sold $15,001 - $50,000 in shares of Lululemon Athletica NASDAQ: LULU on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of Western Digital NASDAQ: WDC on 4/17/2025.
- Sold $15,001 - $50,000 in shares of Zoetis NYSE: ZTS on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of Stryker NYSE: SYK on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of CSX NASDAQ: CSX on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of Ross Stores NASDAQ: ROST on 4/17/2025.
Repligen Trading Down 3.6 %
Shares of RGEN stock traded down $4.61 on Friday, reaching $123.24. The company had a trading volume of 580,989 shares, compared to its average volume of 726,090. The company has a 50-day moving average of $135.03 and a 200-day moving average of $145.32. Repligen Co. has a 12 month low of $102.97 and a 12 month high of $182.52. The stock has a market cap of $6.92 billion, a PE ratio of -241.65, a PEG ratio of 4.54 and a beta of 1.21. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.
Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.35 by $0.04. The firm had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.28 earnings per share. On average, equities analysts forecast that Repligen Co. will post 1.72 earnings per share for the current year.
Hedge Funds Weigh In On Repligen
Hedge funds and other institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its position in Repligen by 4.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 396,150 shares of the biotechnology company's stock worth $50,406,000 after acquiring an additional 18,250 shares in the last quarter. Intrust Bank NA acquired a new stake in Repligen in the 1st quarter valued at about $222,000. Geneva Capital Management LLC lifted its stake in Repligen by 5.9% in the 1st quarter. Geneva Capital Management LLC now owns 143,543 shares of the biotechnology company's stock valued at $18,264,000 after purchasing an additional 7,958 shares during the last quarter. Argent Trust Co bought a new position in Repligen during the first quarter worth about $212,000. Finally, Bank of Nova Scotia acquired a new position in Repligen during the first quarter worth approximately $2,149,000. 97.64% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several brokerages have issued reports on RGEN. Canaccord Genuity Group lowered their price target on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price on the stock in a report on Tuesday, April 29th. Evercore ISI began coverage on shares of Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price target for the company. Royal Bank of Canada dropped their price objective on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 29th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $173.25.
Check Out Our Latest Research Report on RGEN
Insider Buying and Selling at Repligen
In other Repligen news, Director Margaret Pax purchased 250 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 1.20% of the company's stock.
About Representative Shreve
Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election.
Email editor@ballotpedia.org to notify us of updates to this biography.
Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive.
Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.
Repligen Company Profile
(
Get Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
